ArticleBMC endocrine disorders2026
Impact of herpes zoster and post-zoster SGLT2 inhibitors initiation on cardiorenal outcomes in type 2 diabetes mellitus.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThis study aimed to investigate the impact of new-onset herpes zoster (HZ) on the risk of cardiorenal outcomes in patients with type 2 diabetes mellitus (T2DM) and to evaluate whether subsequent initiation of sodium-glucose cotransporter-2 (SGLT2) inhibitors modified this risk.
methodsPatients with T2DM were identified from a territory-wide cohort from 2016 to 2021. The primary outcomes were primary renal composite outcomes (defined as a composite of end-stage renal failure, a 50% decline in estimated glomerular filtration rate [eGFR], or all-cause mortality) and primary cardiovascular composite outcomes (defined as a composite of heart failure hospitalization, myocardial infarction, stroke or all-cause mortality).
resultsNew-onset HZ occurred in 3,306/171,474 patients (incidence rate 5.70/1,000 person-years) and was independently associated with higher risks of the primary renal composite outcomes (adjusted HR 1.42, 95% CI 1.30–1.55) and primary cardiovascular composite outcomes (adjusted HR 1.59, 95% CI 1.42–1.77) in patients with T2DM. This association was more pronounced within the first three months following infection and attenuated thereafter. Among patients who developed HZ, the initiation of SGLT2 inhibitors was associated with a lower risk of adverse renal (HR 0.57, 95% CI 0.42–0.78) and cardiovascular (HR 0.54, 95% CI 0.32–0.91) outcomes.
conclusionsNew-onset HZ was associated with increased cardiorenal risk among patients with T2DM, and subsequent SGLT2 inhibitors initiation was associated with a reduced risk of these adverse events. These findings underscore the significance of HZ prevention and the potential benefits of early initiation of SGLT2 inhibitors post-HZ to mitigate cardiorenal adverse events in patients with T2DM. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.